Disclosure of payments made to HCPs in Ireland

In recent years GSK has challenged the traditional commercial model of pharmaceutical companies with industry-leading improvements to how we do business. Our improvements aim to meet society’s growing expectation for organisations and individuals to act with transparency. This includes relationships between our industry and healthcare professionals (HCPs) or healthcare organisations (HCOs) so all of these interactions are conducted with integrity and transparency.

Cooperation between pharmaceutical companies, regulators, Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been and will always remain valuable partners for GSK. As experts in their field, they provide us with first hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet disparate patient and public health needs.

To ensure all of these interactions are conducted with integrity and transparency, under the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations, from 2016 EFPIA member companies pledged to disclose the payments/transfers of value they make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.

This is now the third year of disclosure of these transfer of values (ToV).

GSK disclosures for Ireland for 2017 may be viewed here 

Key points for 2017 include:

  • Our 2017 data confirm that we continue to lead the industry in its journey towards greater transparency with 100% disclosure on a named individual basis.
  • We continue to implement the Code in the true spirit in which it is intended i.e. we will publish named individual disclosure and only disclose on an aggregate basis only for payments relating to Research and Development (as stipulated under the EFPIA Disclosure Code)
  • For 2017, we had a 100% individual consent rate for our disclosures: We strive to named individual disclosure where required under the Code as the rule and disclose on an aggregate basis only for payments relating to R&D or otherwise by exception. Given how important the relationship between Pharma companies and HCPs is, we want to do everything we can to ensure these relationships are fully transparent so there is no room for any misperceptions of conflicts of interest.

Leading the industry

In recent years GSK has challenged the traditional commercial model of pharmaceutical companies with industry-leading improvements to how we do business. Our improvements aim to meet society’s growing expectation for organisations and individuals to act with transparency.

Our changes at GSK go further than the current industry disclosure codes and therefore others in the industry:  As of 1 January 2016, as part of a number of key changes to how we work with HCPs, GSK ended payments to external HCPs to speak about our prescription medicines or vaccines to audiences who can prescribe or influence prescribing. Since then, GSK also stopped providing financial support directly to individual HCPs to attend medical congresses, and instead now provides funding to independent bodies which select HCPs to attend such congresses.

We continue to work with HCPs for non-promotional activities such as clinical research and advisory activities. Our disclosure figures for example include fees to HCPs to provide GSK with advice on medical and scientific topics. It also includes funding to independent HCOs to provide bursaries to attend medical congresses. Transfers of value to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.

We believe these disclosures will help create a better understanding of how the pharmaceutical industry works with HCPs and HCOs. Given the measures GSK has put in place we seek to increase confidence in, and understanding of, how and why we work with healthcare professions for the sustainable improvement of healthcare and in the best interests of patients.